Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Sarcoma, Alveolar Soft Part 3Sarcoma 3Gliosarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Solitary Fibrous Tumor, Pleural 2Mesothelioma, Malignant 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1

Interventions

AZD 6244 5trametinib 2pirfenidone 2Imatinib Mesylate 2tipifarnib 1peginterferon alfa-2b 1mirdametinib 1cediranib 1cabozantinib 1binimetinib 1Vinblastine 1Methotrexate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibroma, Plexiform × cediranib × Clear all
NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

National Cancer Institute (NCI)

Phase 2 Terminated
26 enrolled 8 charts
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡